Should ARB/CAB combination tablets be continued or withheld preoperatively?
Not Applicable
- Conditions
- Hypertension under treatment with ARB/CAB combination tabletshypertension, general anesthesia
- Registration Number
- JPRN-jRCT1031190027
- Lead Sponsor
- Hayashida Masakazu
- Brief Summary
Continuation of ARB/CCB combination tablets was effective in preventing hypertension before anesthesia. However, it increased a risk of hypotension during anesthesia and increased requirements of vasoconstrictor therapy. Further, it was not effective in preventing postoperative hypertension. Therefore, discontinuation of ARB/CCB combination tablets prior to general anesthesia seemed preferable to their continuation.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- All
- Target Recruitment
- 110
Inclusion Criteria
Surgical patients with hypertension treated with ARB/CAB combination tablets
Exclusion Criteria
Patients having severe comorbidities, including heart disease, and those scheduled for major surgery including cardiac surgery
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Perioperative changes in blood pressure and requirements of vasoactive agents
- Secondary Outcome Measures
Name Time Method Incidences of perioperative complications, including profound hypotension, profound hypertension, and electrocardiographic abnormalities